Page last updated: 2024-08-22

Brilliant Blue and Hyperplasia

Brilliant Blue has been researched along with Hyperplasia in 2 studies

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's2 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Brophy, C; Cheung-Flynn, J; Hocking, KM; Komalavilas, P; Li, FD; Luo, W1
Brophy, C; Cheung-Flynn, J; Hocking, K; Komalavilas, P; Osgood, MJ; Sexton, K; Song, J; Voskresensky, I1

Other Studies

2 other study(ies) available for Brilliant Blue and Hyperplasia

ArticleYear
Brilliant blue FCF is a nontoxic dye for saphenous vein graft marking that abrogates response to injury.
    Journal of vascular surgery, 2016, Volume: 64, Issue:1

    Topics: Animals; Aorta; Benzenesulfonates; Calcium Signaling; Cells, Cultured; Coloring Agents; Cytoprotection; Female; Human Umbilical Vein Endothelial Cells; Humans; Hyperplasia; In Vitro Techniques; Male; Neointima; Organ Culture Techniques; Purinergic P2X Receptor Antagonists; Rats, Sprague-Dawley; Receptors, Purinergic P2X7; Saphenous Vein; Swine; Vascular Grafting; Vascular System Injuries; Vasoconstriction

2016
Use of Brilliant Blue FCF during vein graft preparation inhibits intimal hyperplasia.
    Journal of vascular surgery, 2016, Volume: 64, Issue:2

    Topics: Animals; Benzenesulfonates; Cell Line; Cell Movement; Cell Proliferation; Coloring Agents; Humans; Hyperplasia; Jugular Veins; Models, Animal; Muscle, Smooth, Vascular; Myocytes, Smooth Muscle; Neointima; Organ Culture Techniques; Purinergic P2X Receptor Antagonists; Rabbits; Rats; Receptors, Purinergic P2X7; Saphenous Vein; Signal Transduction; Time Factors; Tissue and Organ Harvesting

2016